The global agitation in delirium management market size was valued at USD 220 million in 2021 and is projected to reach around USD 350 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period. The upsurge in the prevalence of delirium, growing geriatric population, increasing government initiatives, development in treatment options, escalating awareness about agitation in delirium and its management are anticipated to boost the growth of the agitation in delirium management market during the forecasted period. Conversely, obtainability of non-pharmacological alternatives, higher cost of medication, and rising product recalls can be a restraint in the growth of this market.
Research institutes and market players are involved in conducting research and development deeds for analysing the security and efficiency of the drugs for the treatment of agitation in delirium in critically ill ICU patients. For example, in 2020, BioXcel Therapeutics Inc. was conducting clinical trials for examining the safety, effectiveness, tolerability, and for computing the smallest dose of management of dexmedetomidine sublingual film for the treatment of hyperactive delirium (i.e., delirium with agitation) in the intensive care unit (ICU) situation. Moreover, growing product approvals by the governing authorities is anticipated to boost the growth of the market over the forecasted period. For example, on December 9, 2020, Aurobindo Pharma got approval from the U.S. FDA to produce and market Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, 200 g/50 mL and 400 g/100 mL single dose flexible flasks.
The growing prevalence of delirium in ICU patients is projected to help in growth of the hospital pharmacies segment during the estimated period. For example, as per the National Center for Biotechnology Information: 2018 report, worldwide, the occurrence of delirium in ICU was stated to be 32.3%. In the dedicated ICU, the prevalence of delirium was roughly 77% in ventilated burn patients. As per the same source, the occurrence of delirium in the ICU ranged between 45% to 87%.
The COVID-19 pandemic is anticipated to boost the growth of the global agitation in delirium management market over the forecasted period. Owing to the increasing incidences of COVID in patients, researchers are focusing to find the treatment for delirium happening in the infected patients. This is anticipated to help the market growth in the forecasted period.
Second-generation antipsychotics are the fastest growing market. These varieties of drugs have a lower affinity for the dopamine receptors which will lower the side effects. This is the reason that backing to market demand for the global agitation in delirium management.
Some of the first-line agents utilized for excited agitation in grown-ups are antipsychotic containing risperidone, haloperidol, and olanzapine, alongside a benzodiazepine such as lorazepam or midazolam. Rising research on motor-defined clinical subtypes of delirium has augmented the landscape of the global market.
Route of Administration Insights
Based on the route of administration, the global agitation in delirium management market is categorised into oral, intramuscular, and others. Among these, the oral segment is having the largest market share owing to its several benefits. For example, definite oral medicines like haloperidol are widely used for the treatment of delirium. This drug benefits to treat the neurological issues in a more effective without producing nervousness to the patient after medication.
Distribution Channel Insights
On the basis of distribution channel, the global agitation in delirium management market is categorised into hospital pharmacies, retail pharmacies, and online pharmacies. Out of these, the hospital pharmacies segment grasps the largest market share in 2021 and is projected to remain the largest segment during the forecasted period. The hospital pharmacist provides patient care with enhanced medicine use and endorses disease prevention, health, and wellness. They also have specialized skills and ethics and guarantee optimal safety in the circulation of medicine. Therefore, the patient’s condition will remain stable throughout the entire drug therapy.
North America rules the agitation in delirium management market owing to the rising research and development activities by important key players, well-developed healthcare sector, growing prevalence of disease, and rising awareness concerning health in this region.
The adoption of custom-made method to various set of patients such as paediatrics and geriatrics is key to driving paces of the regional market throughout the forecasted period. Regular updates the rules have also assisted strengthen the predictions of market in the U.S., a significant market in North America. American College of Gynecology (ACOG) and the implementation of protocols by the American College of Emergency Physicians are prominent case in point.
Global agitation in delirium management market in the Asia-Pacific and Europe is projected to grow through the forecasted period owing to the growing prevalence of cancer, increase in research and development activities, escalating investment in the healthcare sector and rising government support.
Key Companies Insights
The market for agitation in delirium management is reasonably competitive. With the rising applications of agitation in delirium management, new players are considering to enter the market. The companies are also involved in events like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Agitation in delirium management market, ultimately boosting the market growth.
Some of the key companies working in the global agitation in delirium management market include:
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Limited
• Mylan N.V.
• Pfizer Inc.
• Fresenius Kabi AG
• Novartis AG
• Akorn Incorporated
• Zydus Cadila
• BioXcel Therapeutics, Inc.
• Other players
Some of the Recent Developments:
• In October 2020, BioXcel Therapeutics, Inc. got the authorization for its Investigational New Drug (IND) request for BXCL501 from the Division of Psychiatry Products of the U.S. Food and Drug Administration (FDA). The expected permission is for the management of agitation related to delirium, and presently it’s under Phase 2 of clinical trial.
• In 2019, Fresenius Kabi AG extended its pharmaceutical manufacturing facility in Wilson, Ohio, U.S. The new industrial site would upsurge the construction of affordable generic medications that are used in the hospitals and clinics. The industrial facility will also upsurge the production of drugs necessary for agitation in delirium.
• First-generation Antipsychotics
• Second-generation Antipsychotics
By Route of Administration
By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• North America
o South Korea
• Latin America
o South Africa
o Saudi Arabia